Stocks › KRYS

Krystal Biotech, Inc.

KRYS·Nasdaq·United States United States·USD
$308.89
-6.93 (-2.19%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
KRYS
Krystal Biotech, Inc. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
KRYSS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair

Congressional Trades

Recent trades of KRYS by members of U.S. Congress · 1 on record
All congressional trades →
PoliticianStockTypeFiledTraded
Christopher L. JacobsChristopher L. JacobsHouse · R · NY KRYSKrystal Biotech, Inc. · Stock Purchase
$1,001 - $15,000
Jan 20, 2023 Dec 12, 2022 Filing ↗

Whale Activity

Position changes in KRYS reported for 2026-09-30 by 491 institutional filers
Increased: 176New: 73Held: 57Decreased: 118Closed: 48No prior filing: 19
  • Increased176
  • New73
  • Held57
  • Decreased118
  • Closed48
  • No prior filing19
FilerSharesValueChange
FMR LLC4.4M$1.48Bincreased
BlackRock, Inc.3.6M$1.19Bdecreased
Avoro Capital Advisors LLC2.9M$960.7Mheld
STATE STREET CORP1.4M$472.3Mincreased
VANGUARD PORTFOLIO MANAGEMENT LLC1.3M$428.0Mdecreased
VANGUARD CAPITAL MANAGEMENT LLC1.2M$398.0Mdecreased
Soleus Capital Management, L.P.1.1M$379.0Mincreased
GEODE CAPITAL MANAGEMENT, LLC811.7K$270.0Mincreased
Capital World Investors779.3K$259.2Mincreased
Hood River Capital Management LLC672.0K$223.5Mincreased
PRICE T ROWE ASSOCIATES INC /MD/586.4K$195.0Mdecreased
Redmile Group, LLC527.7K$175.5Mdecreased

Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.

Insider Trading

Net shares bought (+) or sold (−) on the open market by KRYS insiders, by quarter · Form 4
-200.0K-100.0K0100.0K200.0K2025 Q1: -50.8K2025 Q12025 Q2: 02025 Q22025 Q3: -50.0K2025 Q32025 Q4: -55.7K2025 Q42026 Q1: -154.2K2026 Q12026 Q2: -51.6K2026 Q22026 Q3: -75.0K2026 Q32026 Q4: 02026 Q4

Recent Insider Transactions

699 transactions on record · newest first
All insider activity →
InsiderTypeSharesPriceValueDate
Krishnan SumaPresident, R&D · Director · 10% owner Sale −399 $366.56 $146K Sep 4, 2026 Form 4 ↗
Krishnan SumaPresident, R&D · Director · 10% owner Sale −826 $365.41 $302K Sep 4, 2026 Form 4 ↗
Krishnan SumaPresident, R&D · Director · 10% owner Sale −1,329 $364.48 $484K Sep 4, 2026 Form 4 ↗
Krishnan SumaPresident, R&D · Director · 10% owner Sale −565 $363.34 $205K Sep 4, 2026 Form 4 ↗
Krishnan SumaPresident, R&D · Director · 10% owner Sale −1,992 $362.65 $722K Sep 4, 2026 Form 4 ↗
Krishnan SumaPresident, R&D · Director · 10% owner Sale −1,242 $361.61 $449K Sep 4, 2026 Form 4 ↗
Krishnan SumaPresident, R&D · Director · 10% owner Sale −2,320 $360.47 $836K Sep 4, 2026 Form 4 ↗
Krishnan SumaPresident, R&D · Director · 10% owner Sale −3,392 $359.39 $1.2M Sep 4, 2026 Form 4 ↗
Krishnan SumaPresident, R&D · Director · 10% owner Sale −3,180 $358.42 $1.1M Sep 4, 2026 Form 4 ↗
Krishnan SumaPresident, R&D · Director · 10% owner Sale −3,962 $357.57 $1.4M Sep 4, 2026 Form 4 ↗
Krishnan SumaPresident, R&D · Director · 10% owner Sale −3,267 $356.37 $1.2M Sep 4, 2026 Form 4 ↗
Krishnan SumaPresident, R&D · Director · 10% owner Sale −2,006 $355.57 $713K Sep 4, 2026 Form 4 ↗
Krishnan SumaPresident, R&D · Director · 10% owner Sale −520 $354.54 $184K Sep 4, 2026 Form 4 ↗
Krishnan Krish SPresident and CEO · Director · 10% owner Sale −405 $366.56 $148K Sep 4, 2026 Form 4 ↗
Krishnan Krish SPresident and CEO · Director · 10% owner Sale −847 $365.42 $310K Sep 4, 2026 Form 4 ↗
Krishnan Krish SPresident and CEO · Director · 10% owner Sale −1,358 $364.48 $495K Sep 4, 2026 Form 4 ↗
Krishnan Krish SPresident and CEO · Director · 10% owner Sale −573 $363.34 $208K Sep 4, 2026 Form 4 ↗
Krishnan Krish SPresident and CEO · Director · 10% owner Sale −2,010 $362.65 $729K Sep 4, 2026 Form 4 ↗
Krishnan Krish SPresident and CEO · Director · 10% owner Sale −1,214 $361.61 $439K Sep 4, 2026 Form 4 ↗
Krishnan Krish SPresident and CEO · Director · 10% owner Sale −2,266 $360.46 $817K Sep 4, 2026 Form 4 ↗

Fund Holders

Mutual funds and ETFs holding KRYS · SEC Form N-PORT
FundSharesValue% of fundAs of
Select Biotechnology Portfolio
Fidelity Select Portfolios
1.8M$647.8M10.30%Aug 31, 2026
iShares Core S&P Small-Cap ETF
iShares Trust
1.6M$587.4M0.53%Jun 30, 2026
VANGUARD TOTAL STOCK MARKET INDEX FUND
VANGUARD INDEX FUNDS
889.5K$330.6M0.01%Jun 30, 2026
Fidelity Growth Company Fund
Fidelity Mt. Vernon Street Trust
816.1K$293.3M0.30%Aug 31, 2026
SMALLCAP World Fund Inc752.2K$279.6M0.30%Jun 30, 2026
iShares Russell 2000 ETF
iShares Trust
670.9K$249.3M0.30%Jun 30, 2026
VANGUARD SMALL-CAP INDEX FUND
VANGUARD INDEX FUNDS
642.5K$238.8M0.13%Jun 30, 2026
VANGUARD SMALL-CAP GROWTH INDEX FUND
VANGUARD INDEX FUNDS
370.5K$137.7M0.29%Jun 30, 2026
Hood River Small-Cap Growth Fund
Manager Directed Portfolios
329.8K$122.6M1.84%Jun 30, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF
SPDR SERIES TRUST
318.7K$118.5M1.10%Jun 30, 2026

Mutual funds and ETFs whose N-PORT filings list KRYS's shares (CUSIP 501147102), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.

Activist & Passive Stakes

Schedule 13D / 13G beneficial-ownership filings
  • Vanguard Portfolio ManagementSCHEDULE 13G/A · passive (13G) · 1.3M shares4.4%
    Oct 30, 2026 · ↗
  • BlackRock, Inc.SCHEDULE 13G/A · passive (13G) · 3.4M shares11.6%
    Oct 27, 2026 · ↗

Corporate Lobbying

Estimated quarterly lobbying spending reported under the LDA, filings naming Krystal Biotech, Inc. as client

No lobbying filings found naming Krystal Biotech, Inc. as the client.

Government Contracts

Federal awards to Krystal Biotech, Inc. · USAspending

No federal contract awards found for Krystal Biotech, Inc..

U.S. Patents

Recent USPTO applications naming Krystal Biotech, Inc.

No USPTO patent applications found for Krystal Biotech, Inc..

Annual Financials

From KRYS's 10-K filings · XBRL
Fiscal yearFY2025FY2024FY2023FY2022FY2021
Revenue$389.1M$290.5M$50.7M$0$0
Operating income$161.3M$65.7M-$109.6M-$145.2M-$68.3M
Net income$204.8M$89.2M$10.9M-$140.0M-$69.6M
Diluted EPS$6.84$3.00$0.39-$5.49-$3.13
Operating cash flow$200.9M$123.4M-$88.8M-$100.6M-$47.9M
Cash and equivalents$496.3M$344.9M$358.3M$161.9M$341.2M
Total assets$1.33B$1.06B$818.4M$558.5M$626.3M
Total liabilities$114.2M$109.5M$39.7M$36.2M$32.7M
Shareholders' equity$1.22B$946.4M$778.6M$522.2M$593.6M

As Krystal Biotech, Inc. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 17, 2026 ↗

Stock Splits

Every split and reverse split in the price history

No stock splits in KRYS's price history.

Material Events (8-K)

Corporate events filed with the SEC
  • 8-K · Items 2.02, 9.01Results of operationsNov 2, 2026
    EDGAR ↗
  • 8-K · Items 7.01, 9.01Reg FD disclosureOct 15, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 9.01Results of operationsAug 3, 2026
    EDGAR ↗
  • 8-K · Items 8.01, 9.01Other eventsJul 21, 2026
    EDGAR ↗
  • 8-K · Items 5.07Shareholder voteMay 20, 2026
    EDGAR ↗
  • 8-K · Items 9.01May 4, 2026
    EDGAR ↗

About Krystal Biotech, Inc.

From SEC EDGAR company records
Industry (SIC 2836)Biological Products, (No Diagnostic Substances)
SectorHealthcare
HeadquartersPITTSBURGH, PA